Investor Presentaiton
.
Established Customer Base and Broad Global Support
Safety
• 10-year follow-up
data proved no
detectable retina
damage
Efficacy
Randomized controlled
trials showed improved
vision and improved
retinal sensitivity
• Over 135 published
studies
.
&
Efficiency
More treatable
patients
Improved patient
pass-through rates
Reduce financial cost
and treatment burden
EA
$
Economics
Using anti-VEGF and
MicroPulse therapy may
reduce treatment burden
and costs
=
Established
More than 1 million
patients treated
Over 1,200 systems
sold
• More than 65 countries
served
17
THE GEORGE
WASHINGTON
UNIVERSITY
WASHINGTON DC
Hospital
de Olhos
ARARAQUARA
STANFORD
UNIVERSITY
UNIVERSITY OF IOWA
HEALTH CARE
Wills Eye Hospital Moorfields Eye Hospital NHS
America's First World's Best
NHS Foundation Trust
Department of Ophthalmology
and Visual Sciences
Tufts
Medical
Center
1902
AUBMC
AMERICAN UNIVERSITY of BEIRUT MEDICAL CENTER
المتركز الطبي في الجامعة الأميركية في بيروت
UCDAVIS
EYE CENTER
KAISER
PERMANENTE®
ERSITAS
°
STUDI
MCCXXII
PADUAD
UNIVERSITÀ
DEGLI STUDI
DI PADOVA
New York Eye and Ear Infirmary
of Mount Sinai
IRIDEXView entire presentation